10x Genomics director sells 5,723 shares

The reported transactions followed a Rule 10b5-1 trading plan adopted on March 13, 2026.

Rhea-AI Filing Summary

10x Genomics, Inc. director Suliman Shehnaaz sold 5,723 shares of Class A Common Stock in five reported transactions on September 22, 2026. The reported weighted average sale prices were $78.1959, $79.5114, $80.8164, $81.6699 and $82.2768 per share. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.

Insider Trade Summary 10b5-1

Net Seller: 5,723 shares

Net Sell 5 txns

Insider SULIMAN SHEHNAAZ

Role Director

Sold 5,723 shs ($465K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	292	$78.1959	$23K
Sale	Class A Common Stock F1, F3	614	$79.5114	$49K
Sale	Class A Common Stock F1, F4	1,325	$80.8164	$107K
Sale	Class A Common Stock F1, F5	2,270	$81.6699	$185K
Sale	Class A Common Stock F1, F6	1,222	$82.2768	$101K

Holdings After Transaction: Class A Common Stock — 23,792 shares (Direct)

Footnotes (6)

1. F1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026.
2. F2. This transaction was executed in multiple trades at prices ranging from $77.76 to $78.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. This transaction was executed in multiple trades at prices ranging from $79.075 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. F4. This transaction was executed in multiple trades at prices ranging from $80.08 to $81.0769, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. F5. This transaction was executed in multiple trades at prices ranging from $81.08 to $82.0791, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
6. F6. This transaction was executed in multiple trades at prices ranging from $82.08 to $82.56, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Total shares sold: 5,723 shares Shares sold and weighted average sale price: 292 shares at $78.1959 per share Shares sold and weighted average sale price: 614 shares at $79.5114 per share +3 more

6 metrics

Total shares sold 5,723 shares Five transactions on September 22, 2026

Shares sold and weighted average sale price 292 shares at $78.1959 per share September 22, 2026

Shares sold and weighted average sale price 614 shares at $79.5114 per share September 22, 2026

Shares sold and weighted average sale price 1,325 shares at $80.8164 per share September 22, 2026

Shares sold and weighted average sale price 2,270 shares at $81.6699 per share September 22, 2026

Shares sold and weighted average sale price 1,222 shares at $82.2768 per share September 22, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Class A Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to the Reporting Person's Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

Class A Common Stock technical

"Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TXG shares did director Suliman Shehnaaz sell?

Suliman Shehnaaz sold 5,723 shares of Class A Common Stock across five reported transactions on September 22, 2026.

What prices did Suliman Shehnaaz receive for TXG shares?

The reported weighted average sale prices were $78.1959 per share for 292 shares, $79.5114 for 614 shares, $80.8164 for 1,325 shares, $81.6699 for 2,270 shares, and $82.2768 for 1,222 shares. Each transaction occurred on September 22, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/24/2026 - 04:31 PM Accepted by SEC EDGAR 09/24/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SULIMAN SHEHNAAZ

(Last) (First) (Middle)

C/O 10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/22/2026		S(1)		292	D	$78.1959(2)	29,223	D
Class A Common Stock	09/22/2026		S(1)		614	D	$79.5114(3)	28,609	D
Class A Common Stock	09/22/2026		S(1)		1,325	D	$80.8164(4)	27,284	D
Class A Common Stock	09/22/2026		S(1)		2,270	D	$81.6699(5)	25,014	D
Class A Common Stock	09/22/2026		S(1)		1,222	D	$82.2768(6)	23,792	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026.

2. This transaction was executed in multiple trades at prices ranging from $77.76 to $78.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $79.075 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $80.08 to $81.0769, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. This transaction was executed in multiple trades at prices ranging from $81.08 to $82.0791, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

6. This transaction was executed in multiple trades at prices ranging from $82.08 to $82.56, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Randy Wu, as Attorney-in-Fact for Shehnaaz Suliman	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)